Less IS less: a randomised controlled trial comparing cautious and rapid nalbuphine dosing regimens

M Woollard, R Whitfield, K Smith, T Jones, G Thomas, G Thomas, C Hinton

Objective: This study aimed to determine which of two paramedic administered nalbuphine dosing regimens combined the greater analgesic effect with the minimum of adverse events.

Methods: Patients suffering from chest pain or trauma were randomised to receive either a rapid dosing regimen (10 mg over 30 seconds, repeated once after three minutes if pain score remained above three) or a cautious regimen (5 mg over two minutes, repeated at three minute intervals if pain score remained above three to a maximum dose of 20 mg). Data were collected on analgesic effectiveness, changes in vital signs, and patient reported side effects.

Results: The pain score fell by a mean of 4.29 and 3.49 in the rapid and cautious regimen groups respectively (difference = 0.79, 95% CI 0.09 to 1.5, p = 0.028). However, over half the patients in both groups continued to suffer significant pain on arrival at hospital. There were no significant changes in vital signs after nalbuphine, but there was a greater incidence of patient reported drowsiness in rapid regimen patients (42% compared with 21%, 95% CI = 6.96 to 34.12%, p = 0.003).

Conclusion: A rapid dosing regimen of nalbuphine using 10 mg increments is more effective than and equally as safe as a cautious regimen using 5 mg increments. Further research is required to determine if a maximum dose exceeding 20 mg would result in fewer patients continuing to suffer significant pain before arrival at hospital.

Until 2001, nalbuphine was the only parenteral analgesic licensed for use by UK paramedics. The Medicines Act was then amended to permit paramedics to use morphine, in a dose limited to 10 mg. The adoption of morphine has been slow, perhaps because of the inexperience of UK ambulance services in managing controlled drugs. Nalbuphine, however, has been shown to be safe and effective in the prehospital environment when used for a variety of conditions.1–4

The manufacturer’s datasheet for nalbuphine recommends an initial dose of 10 to 20 mg for a 70 kg patient, repeated after 30 minutes if pain relief remains inadequate. Severe respiratory depression has been reported after use of a similar regimen by paramedics.5 A subsequent survey of 115 patients treated with a conservative regimen (mean dose 6 mg) reported no clinically significant changes in respiratory rate or blood pressure and a mean decrease in pain score of four on a 10 point scale, although analgesia was inadequate for 60% of patients.6

This study aimed to determine whether a cautious or rapid nalbuphine regimen combined the greater analgesic effect with the minimum of adverse events.

METHODS

Study design

This randomised controlled trial compared two dosing regimens of paramedic administered nalbuphine hydrochloride (Du Pont Pharmaceuticals Limited, Letchworth Garden City, UK). Subjects in the rapid regimen group received 10 mg nalbuphine over 30 seconds, repeated once after three minutes if their pain score remained above three. Those treated with the cautious regimen received 5 mg nalbuphine over two minutes, repeated at three minute intervals if their pain score remained above three to a maximum dose of 20 mg.

Patients were asked to score their pain using a numerical rating scale (NRS) graded from 0–10, with four or higher indicating moderate to severe pain. The NRS has been recommended for use in a variety of settings,7 avoids under-estimation or over-estimation of pain by independent observers,4 and correlates well with the validated visual analogue scale.8–12 Paramedics gave a standardised explanation of the NRS:

“On a scale of 0 to 10, with zero representing no pain and 10 being the worst pain you can imagine, what score would you give to the pain you are experiencing now?”

Patients aged 18 or over with pain scores of more than three associated with long bone injury, burns, or ischaemic heart disease were recruited. Patients not meeting the criteria for nalbuphine administration or who had previously received analgesia (other than Entonox) were excluded.

Six hundred forms identifying the regimen to be used were randomised using statistical software (SPSS, version 9.0.0, SPSS Inc, Chicago), assigned a unique number, and placed in opaque envelopes. These were distributed in consecutively numbered groups of 10 to each participating ambulance. Paramedics opened the envelope with the lowest remaining number after recruitment of each patient.

If the attending paramedic judged the patient was not too distressed, verbal informed consent was obtained. An information sheet, including a form to indicate their wish to withdraw their data from the study, was given to all patients after hospital admission. Ethics approval was obtained from the Bro Taf and North Wales Health Authority (Central and East) committees.

Sample sizes for a range of outcome variables were calculated and the largest selected for adoption. Based on a 1.74% incidence of nausea in a previous study,13 152 subjects were required in total to detect a between groups difference of 10% with an α of 5% and a power of 90% (χ² test).

Outcome measures and statistical analysis

Between groups comparisons were made for homogeneity, analgesic efficacy, changes in vital signs, side effects, and for evidence of antagonism of hospital administered opioids.
Data were analysed using SPSS (version 9.0.0, SPSS Inc, Chicago, USA). The Mann-Whitney U test was used for between groups comparisons of non-parametric data. Student’s unpaired t test was used for between groups comparisons of changes in pain score and pulse rate. Fisher’s exact test was used for analysis of contingency tables. StatsDirect (version 1.9.8, CamCode, Ashwell, UK) was used to calculate p values and 95% confidence intervals for differences in proportions.

RESULTS
Recruitment
Recruitment is described in the Consort flowchart (fig 1).13

Heterogeneity of groups
Before nalbuphine administration there were no significant between groups differences in age, ratio of male to female subjects, on-scene time, journey time to hospital, ratio of chest pain to trauma patients, vital signs or pain scores (data available on request).

Analgesic efficacy and side effects
The rapid dosing regimen resulted in a significantly greater reduction in pain score. There were no significant between groups differences for changes in vital signs after nalbuphine. However, significantly more side effects occurred in the rapid regimen group, largely explained by a greater incidence of patient reported drowsiness (table 1).

Hospital staff reported signs of antagonism to hospital administered opioids in two patients in each group.

DISCUSSION
Rapid dosing resulted in a greater decrease in pain score. Although the difference of 0.79 is small, it represents a benefit that patients can perceive. However, over half the patients in both groups continued to suffer from significant pain before arrival at hospital.

Rapid regimen patients suffered significantly more patient reported side effects, largely accounted for by an increased incidence of patient reported drowsiness. This was not associated with significant changes in Glasgow coma scores,
however, and it is suggested that drowsiness may be a beneficial effect for distressed patients.

No antiemetic agent was administered to patients during this study. The incidence of nausea or vomiting was higher in the limited evidence available suggested that it did occur. This has been reported in a previous study, although others have not observed this effect. In conclusion, a rapid dosing regimen of nalbuphine is more effective than and equally as safe as a cautious regimen. The incidence of nausea or vomiting is significant for both regimens, and research is required to determine an optimum antemetic drug. Although pain scores fell in both groups, over half of all patients continued to suffer from significant pain before arrival at hospital. Despite this, paramedics often failed to administer the maximum permitted dose. Further research is required to determine why this was the case, and whether the availability of a higher maximum dose of nalbuphine (or the use of morphine) would result in a reduction in the proportion of patients continuing to suffer pain despite paramedic administered analgesia.

ACKNOWLEDGEMENTS

We thank Dr Robert Newcombe, who provided valuable advice on statistical methodology, and Chris Moore, who helped prepare much of the study paperwork. Comments made by Professor Douglas Chamberlain and Dr Mick Colquhoun and three anonymous reviewers helped improve early drafts of this paper.

Contributors

Richard Whitfield conceived the idea for this research. Malcolm Woollard, Tim Jones, Richard Whitfield, and Gwyn Thomas designed the study. Malcolm Woollard analysed the data and wrote the first draft of this paper. Richard Whitfield, Ken Smith, Glyn Thomas, Christine Hinton, and Gwyn Thomas collected the study data, contributed to the study design, and edited the paper. Malcolm Woollard is the study guarantor.

Table 1 Analgesic efficacy and side effects

<table>
<thead>
<tr>
<th></th>
<th>Rapid regimen(2-10 mg)</th>
<th>Cautious regimen(4-5 mg)</th>
<th>Difference</th>
<th>p Value for difference (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean total dose of nalbuphine</td>
<td>14.8 mg</td>
<td>10.7 mg</td>
<td>4.1 mg</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Mean change in pain score</td>
<td>4.29</td>
<td>3.49</td>
<td>0.79</td>
<td>0.028 (0.09 to 1.5)</td>
</tr>
<tr>
<td>Patients with a pain score &gt;3 immediately before A&amp;E admission (%)</td>
<td>44 (53)</td>
<td>48 (55)</td>
<td>2%</td>
<td>0.761 (17.0 to 12.8%)</td>
</tr>
<tr>
<td>Patients receiving hospital analgesia within 30 minutes of arrival (%)</td>
<td>8 (15)</td>
<td>6 (11)</td>
<td>4%</td>
<td>0.583 (10.0 to 17.1%)</td>
</tr>
<tr>
<td>Change in pulse rate</td>
<td>−2.29</td>
<td>−1.63</td>
<td>0.66</td>
<td>0.579</td>
</tr>
<tr>
<td>Change in systolic BP</td>
<td>−1.75</td>
<td>−6.28</td>
<td>4.53</td>
<td>0.108</td>
</tr>
<tr>
<td>Change in GCS</td>
<td>−0.14</td>
<td>0.23</td>
<td>0.36</td>
<td>0.348</td>
</tr>
<tr>
<td>Any side effect (%)</td>
<td>51 (62)</td>
<td>36 (41)</td>
<td>21%</td>
<td>0.004 (6.0 to 35.0%)</td>
</tr>
<tr>
<td>Drowsiness (%)</td>
<td>35 (42)</td>
<td>19 (21)</td>
<td>21%</td>
<td>0.003 (7.0 to 34.1%)</td>
</tr>
<tr>
<td>Dizziness (%)</td>
<td>21 (25)</td>
<td>15 (17)</td>
<td>8%</td>
<td>0.143 (3.8 to 20.8%)</td>
</tr>
<tr>
<td>Nausea or vomiting (%)</td>
<td>17 (21)</td>
<td>14 (16)</td>
<td>5%</td>
<td>0.338 (6.9 to 16.6%)</td>
</tr>
</tbody>
</table>

Authors’ affiliations

M Woollard, R Whitfield, Pre-hospital Emergency Research Unit, Welsh Ambulance Services NHS Trust/University of Wales College of Medicine, Cardiff, UK
K Smith, T Jones, G Thomas, G Thomas, C Hinton, Welsh Ambulance Services NHS Trust

Funding: none.

Conflicts of interest: none declared.

REFERENCES